Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer

Cancer Science

Volumn 103, Issue 7, 2012, Pages 1272-1279

  Onishi, Hideya ^a   Morifuji, Yoshihiro ^a   Kai, Masaya ^a   Suyama, Kumi ^a   Iwasaki, Hironori ^a   Katano, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPAMINE; FLUOROURACIL; GEMCITABINE; HEDGEHOG INHIBITOR; PROTEIN INHIBITOR; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; FEMALE; FLOW CYTOMETRY; FLUOROURACIL; HEDGEHOG PROTEINS; HUMANS; IMMUNOBLOTTING; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREATIC NEOPLASMS; RECEPTORS, G-PROTEIN-COUPLED; RNA INTERFERENCE; TRANSCRIPTION FACTORS; VERATRUM ALKALOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863334314     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02297.x     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Genes Dev 2011; 15: 3059-87.
3. Pasca di Magliano M, Hebrok M. Hedgehog signaling in cancer formation and maintenance. Nat Rev Cancer 2003; 3: 903-11.
4. Low JA, de Sauvage FJ. Clinical experience with hedgehog pathway inhibitors. J Clin Oncol 2010; 28: 5321-6.
5. Tremblay MR, Lescarbeau A, Grogan MJ. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem 2009; 52: 4400-18.
6. Rudin CM, Hann CL, Laterra J et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0499. N Engl J Med 2009; 361: 1173-8.
7. Buonamici S, Williams J, Morrissey M et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2010; 2: 51ra70.
8. Tremblay MR, Nesler M, Weatherhead R, Castro AC. Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy. Expert Opin Ther Pat 2009; 19: 1039-56.
9. Yang H, Xiang J, Wang N et al. Converse conformational control of smoothened activity by structurally related small molecules. J Biol Chem 2009; 284: 20876-84.
10. Katoh Y, Katoh M. Hedgehog signaling pathway and gastric cancer. Cancer Biol Ther 2005; 4: 1050-4.
11. Onishi H, Katano M. Hedgehog signaling pathway as a therapeutic target in various types of cancer. Cancer Sci 2011; 102: 1756-60.
12. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problem) for cancer therapy. Cancer Res 1998; 58: 1408-16.
13. Onishi H, Kai M, Odate S et al. Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer. Cancer Sci 2011; 102: 1144-50.
14. Sasabe E, Zhou X, Li D et al. The involvement of hypoxia-inducible factor-1alpha in the susceptibility to gamma-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells. Int J Cancer 2007; 120: 268-77.
15. Hao J, Song X, Song B et al. Effects of lentivirus mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. Cancer Gene Ther 2008; 15: 449-55.
16. Liu L, Ning X, Sun L et al. Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci 2008; 99: 121-8.
17. Nardinocchi L, Puca R, Sacchi A, D'Orazi G. Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Mol Cancer 2009; 8: 1.
18. Rohwer N, Dame C, Haugstetter A et al. Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. PLoS One 2010; 5: e12038.
19. Stiehl DP, Jelkmann W, Wenger RH, Hellwig-Bürgel T. Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway. FEBS Lett 2002; 512: 157-62.
20. Majumder PK, Febbo PG, Bikoff R et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004; 10: 594-601.
21. Richard DE, Berra E, Gothié E, Roux D, Pouysségur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1 . J Biol Chem 1999; 274: 32631-7.
22. Koukourakis MI, Simopoulos C, Polychronidis A et al. The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status? Anticancer Res 2003; 23: 1673-80.
23. Mayerhofer M, Valent P, Sperr WR, Griffin JD, Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002; 100: 3767-75.
24. Luwor RB, Lu Y, Li X, Mendelsohn J, Fan Z. The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 2005; 24: 4433-41.
25. Jones MK, Szabó IL, Kawanaka H, Husain SS, Tarnawski AS. von Hippel Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis. FASEB J 2002; 16: 264-6.
26. Olive KP, Jacobetz MA, Davidson CJ et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457-61.
27. Wykoff CC, Beasley NJ, Watson PH et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60: 7075-83.
28. Koong AC, Mehta VK, Le QT et al. Pancreatic tumors show high levels of hypoxia. Int J Radiat Biol Phys 2000; 48: 919-22.
29. Hirotsu M, Setoguchi T, Sasaki H et al. Smoothened as a new therapeutic target for human osteosarcoma. Mol Cancer 2010; 9: 5.
30. Thayer SP, di Magliano MP, Heiser PW et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003; 425: 851-6.
31. Nagai S, Nakamura M, Yanai K et al. Gli1 contributes to the invasiveness of pancreatic cancer through matrix metalloproteinase-9 activation. Cancer Sci 2008; 99: 1377-84.